KSCM
BIOT

Kamunting Street Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Kamunting Street Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-317,924
Closed -$3.07M – 96
2021
Q2 		$3.07M Buy
+317,924
New +$3.09M 1.24% 29

Other funds holding BIOT

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Kamunting Street Capital Management's BIOT Position: Q3 2021 in Review

Kamunting Street Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2021, closing a stake of 317,924 shares — an estimated $3.07M sold.

Kamunting Street Capital Management first reported a position in BIOT in Q2 2021 and held it in 1 quarter. The position peaked at $3.07M in Q2 2021. 58 funds tracked by Wall St. Rank hold BIOT as of Q3 2021.

  • Kamunting Street Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2021 after selling out during the quarter.
  • Kamunting Street Capital Management sold 317,924 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2021, an estimated $3.07M.
  • Kamunting Street Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 1 quarter.
  • Kamunting Street Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $3.07M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2021.

Based on Kamunting Street Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.